EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Nassar, Amin
Adib, Elio
Feng, Jamie
Aredo, Jacqueline V.
Parikh, Kaushal
Harris, Jeremy Phillip
Manana, Ana I. Velazquez
Ragavan, Meera Vimala
Lin, Jessica Jiyeong
Piotrowska, Zofia
Fitzgerald, Bailey Gleason
Grohe, Christian
Sankar, Kamya
Neal, Joel W.
Wakelee, Heather A.
Shepherd, Frances A.
Herbst, Roy S.
Naqash, Abdul Rafeh
Goldberg, Sarah B.
Kim, So Yeon
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Stanford Canc Inst, Stanford, CA USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Calif Irvine, Orange, CA USA
[7] Univ Calif San Francisco, San Francisco, CA USA
[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Icahn Sch Med Mt Sinai, New York, NY USA
[11] ELK Berlin, Dept Resp Dis, Berlin, Germany
[12] Cedars Sinai Med Ctr, Los Angeles, CA USA
[13] Stanford Univ, Med Ctr, Stanford, CA USA
[14] Stanford Hosp & Clin, Stanford, CA USA
[15] Univ Hlth Network, Princess Margaret, Toronto, ON, Canada
[16] Yale New Haven, Yale Sch Med, Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[17] Univ Oklahoma Hlth Sci, Stephenson Canc Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8567
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Spontaneously expectorated EGFR-mutant non-small-cell lung cancer
    Sumi, Toshiyuki
    Terai, Kotomi
    Chiba, Hirofumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (11) : 1094 - 1095
  • [22] BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).
    Garcia Campelo, Rosario
    Moran, Teresa
    Cardenal, Felipe
    Alonso-Jaudenes Curbera, Guillermo
    Carcereny Costa, Enric
    Pallares, Cinta
    Camps, Carlos
    Insa, Amelia
    Lopez-Vivanco, Guillermo
    Porta, Rut
    Bastus, Roma
    Isla, Dolores
    Reguart, Noemi
    Bover, Isabel
    Majem, Margarita
    Massuti, Bartomeu
    Luis Ramirez, Jose
    Drozdowskyj, Ana
    Karachaliou, Niki
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [24] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2016, 17
  • [25] REVERSIBLE VERSUS IRREVERSIBLE EGFR TYROSINE-KINASE INHIBITORS FOR NON-SMALL-CELL LUNG CANCER (NSCLC): A PRECLINICAL AND PHARMACOKINETIC COMPARISON
    Liederer, B. M.
    Friess, T.
    Shames, D.
    Wright, M.
    Hop, C. E. C. A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [26] Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Oxnard, G. R.
    Janjigian, Y. Y.
    Arcila, M. E.
    Kris, M. G.
    Ladanyi, M.
    Azzoli, C. G.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-small cell lung cancer following progression on EGFR tyrosine kinase inhibitors (ILLUMINATE)
    Lee, Chee Khoon
    Mersiades, Antony
    Mitchell, Jenna
    Brown, Chris
    Jurkovic, Hannora
    Solomon, Ben
    John, Thomas
    Stockler, Martin
    Yang, James Chi-Hsin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 197 - 198
  • [28] The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Fei Zhou
    Haoyue Guo
    Yang Xia
    Xiuning Le
    Daniel S. W. Tan
    Suresh S. Ramalingam
    Caicun Zhou
    Nature Reviews Clinical Oncology, 2025, 22 (2) : 95 - 116
  • [29] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [30] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Maria Martinez-Navarro, Elena
    Rebollo, Joseba
    Gonzalez-Manzano, Ramon
    Sureda, Manuel
    Evgenyeva, Elena
    Valenzuela, Belen
    Jose Fernandez, Francisco
    Forteza, Jeronimo
    Brugarolas, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (11): : 812 - 818
12345